BackBonus Biogroup Overview

Bonus Biogroup Total Current Liabilities

Track Bonus Biogroup's total current liabilities ($16M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$16.31M
↑ 46.58% YoYΔ $5.18M vs prior year quarter

Peer trimmed avg / median

Loading

Bonus Biogroup Total Current Liabilities History

Loading

Bonus Biogroup vs. peers: Total Current Liabilities Comparison

Loading

Bonus Biogroup Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bonus Biogroup (BBIXF) FAQ

The latest total current liabilities for BBIXF is $16M as of June 2026. That compares with $11M in the prior-year period — up 46.6% year over year. Investors often review this figure alongside Bonus Biogroup's historical trend and sector peers before judging valuation or financial health.

Over the past year, BBIXF's total current liabilities moved from $11M to $16M — a 46.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bonus Biogroup's operating scale or balance-sheet position.

A total current liabilities figure of $16M for BBIXF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BBIXF's total current liabilities ($16M), review year-over-year change from $11M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bonus Biogroup's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.